IP Library Granted Patent US 10,092,548
Granted Patent B2
US 10,092,548 · App. 14/335,895 · Granted Oct 9, 2018

Pharmaceutical compositions for preventing or treating angiogenic diseases comprising inhibitors of NUP153 gene expression or NUP153 activity as active ingredient

Inventors: Ho Jeong Kwon (Seoul, KR); Nam Hee Kim (Seoul, KR)
Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
A61K31/4188C12N15/1138G01N33/5023G01N33/6875C12N2310/11C12N2310/3233G01N2800/7014
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,092,548
App. No.
14/335,895
Granted
Oct 9, 2018
Kind
B2
Abstract

The present invention provides a pharmaceutical composition for preventing or treating angiogenic diseases comprising inhibitors of NUP153 gene expression or NUP153 activity as active ingredient and a method for screening an agent for preventing or treating angiogenic diseases. According to the present invention, inhibition of the NUP153 gene expression or the NUP153 activity reduces export of mRNA of a pro-angiogenic factor (VEGF, HGF and bFGF) from nucleus. In addition, inhibition of the NUP153 gene expression or the NUP153 activity has effect that angiogenesis are inhibited by inhibition of invasion and tube formation in a dose-dependent manner without showing toxicity. Therefore, the pharmaceutical composition of the present invention may be used for preventing or treating a variety of angiogenesis-related diseases, and the method for screening of the present invention may be valuably used in finding a new agent for preventing or treating angiogenic diseases.

Claims (2)

1. A method for treating a disease selected from the group consisting of cancer, diabetic retinopathy, retinopathy of prematurity, neovascular glaucoma, and proliferative retinopathy, the method comprising:

administering to a subject in need thereof a biotinylated OMe-Syn of Compound 1:

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2014
From: KWON, HO JEONG; KIM, NAM HEE
To: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
Reel/Frame 033361/0360 →
Priority Claims (1)
KR 10-2013-0085670 · Jul 19, 2013 · national
Continuity (1)
Related Publication 20150023973A1 · Jan 22, 2015